Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
NCT03739840 · UCB Biopharma SRL · PHASE3 · terminated · last registry update 2022-12-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure” | – | Registry record, UCB Biopharma SRL |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABRA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-13Results posted on the registry: Wake Forest University Health Sciences, Propofol + Methohexital (NCT04187196)
- 2023-08-01Also stopped (withdrawn): University of New Mexico, Acamprosate (Campral) + Acamprosate (NCT00655967)
- 2023-03-09Results posted on the registry: Northwell Health, Ketamine + Methohexital (NCT01881763)
- 2022-12-20Results posted on the registry: Mayo Clinic, Acomprosate (NCT04287920)
- 2022-03-24Results posted on the registry: Mayo Clinic, Gabapentin + Benzodiazepines (NCT03012815)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision